GSK Makes ADC Pipeline Comeback With Mersana Deal

Pays $100m Upfront

The UK major has teamed up with the US biotech to develop the latter’s HER-2 targeted antibody-drug conjugate, a couple of years after the approval of Blenrep, in what is becoming an increasingly competitive space.  

Purple Cells
GSK Already Has One ADC Product On The Market For Multiple Myeloma • Source: Shutterstock

GlaxoSmithKline Pharmaceuticals Ltd. is diving back into antibody-drug conjugate R&D with new partner Mersana Therapeutics, Inc., paying $100m upfront to develop its preclinical ADC asset for HER-2 expressing tumors.

Under the terms of the deal, GSK will acquire an exclusive option to co-develop and commercialize Mersana’s XMT-2056 which targets...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip